Objective To study the effect of dexmedetomidine combined with ketamine anesthesia on interventional therapy of children with congenital heart disease (CHD). Methods 40 cases of congenital heart disease were treated with catheter intervention from January 2013 to January 2017. The changes of pulmonary arterial pressure and the effect of anesthesia were compared before and after operation. Results 40 cases of children without surgical deaths, 36 cases of successful closure, the success rate of 90% of the operation, the patient after catheter intervention surgery after the results of the test were better than before and after treatment of children with pulmonary artery pressure (P<0.05), and the anesthesia effect was good in children. Conclusion The effect of dexmedetomidine combined with ketamine on the treatment of cardiac catheterization in children with congenital heart disease can achieve good results. The success rate of operation is high and safe, and it is highly reliable.

Objective To explore the efficiency and adverse effects of the effective EP ( etoposide+cisplatin) therapy and its subsequent maintenance therapy with different durations in patients with small cell lung cancer ( SCLC ) . Methods Clinical data of 104 SCLC patients diagnosed and treated at the Jilin Province Cancer Hospital between September 2010 and December 2013 were retrospectively analyzed.Among them, 35 patients were subsequently treated with a 4?week maintenance therapy following the original therapeutic regimen after the effective EP therapy (4?week maintenance therapy group), 35 patients were treated with a subsequent 6?week maintenance therapy ( 6?week maintenance therapy group ) , and 34 patients were treated without maintenance therapy ( control group) .52 patients were in limited stage, and 52 patients were in extensive stage. The progression?free survival (PFS), overall survival (OS) and adverse effects in the 4?week maintenance therapy group, 6?week maintenance therapy group and control group were analyzed. Results The median PFS in the control group, 4?week maintenance therapy group and 6?week maintenance therapy group was 4.0, 3.5, and 4.0 months, respectively, and the median OS was 9.0, 10.0 and 12.0 months, respectively, showing no significant difference among the groups (P>0.05 for all). The median PFS was prolonged by 2 months as compared with the control group after the 4?week maintenance therapy in the patients with complete remission in first?line chemotherapy ( P=0.041) , while the median OS was not improved ( P=0. 131). Neither the median PFS nor median OS showed statistically significant difference between each two groups in the patients with partial remission in first?line chemotherapy ( P>0.05 for all) . In the limited stage, the median PFS in the control group, 4?week maintenance therapy group, and 6?week maintenance therapy group was 5.0, 6.5, and 4.0 months, respectively, and median OS was 11.0, 13.5, and 13.0 months, respectively, the differences showed no statistical significance ( P>0.05 for all) . In the extensive stage, the median PFS in the control group, 4?week maintenance therapy group, and 6?week maintenance therapy group was 3.0, 3.0, and 3.5 months, respectively, showing significant differences ( P=0.015);the median OS was 6.5, 8.0, and 8.0 months, respectively, presenting no statistically significant differences (P=0.096). In addition, the PFS in the 6?week maintenance therapy group was significantly improved as compared with that in the control group ( P=0. 016 ) . Compared with the control group, the incidence rates of nausea ( grade 3?4 ) , vomiting, hypodynamia, leukopenia, neutropenia, and thrombocytopenia in the 4?week maintenance therapy group and 6?week maintenance therapy group were increased significantly ( P<0.05 for all) , however, the side effects were tolerable. Conclusion Prolonging the treatment cycle of EP therapy can improve the PFS in SCLC patients in first?line CR chemotherapy and extensive stage.

Objective To explore the efficiency and adverse effects of the effective EP ( etoposide+cisplatin) therapy and its subsequent maintenance therapy with different durations in patients with small cell lung cancer ( SCLC ) . Methods Clinical data of 104 SCLC patients diagnosed and treated at the Jilin Province Cancer Hospital between September 2010 and December 2013 were retrospectively analyzed.Among them, 35 patients were subsequently treated with a 4?week maintenance therapy following the original therapeutic regimen after the effective EP therapy (4?week maintenance therapy group), 35 patients were treated with a subsequent 6?week maintenance therapy ( 6?week maintenance therapy group ) , and 34 patients were treated without maintenance therapy ( control group) .52 patients were in limited stage, and 52 patients were in extensive stage. The progression?free survival (PFS), overall survival (OS) and adverse effects in the 4?week maintenance therapy group, 6?week maintenance therapy group and control group were analyzed. Results The median PFS in the control group, 4?week maintenance therapy group and 6?week maintenance therapy group was 4.0, 3.5, and 4.0 months, respectively, and the median OS was 9.0, 10.0 and 12.0 months, respectively, showing no significant difference among the groups (P>0.05 for all). The median PFS was prolonged by 2 months as compared with the control group after the 4?week maintenance therapy in the patients with complete remission in first?line chemotherapy ( P=0.041) , while the median OS was not improved ( P=0. 131). Neither the median PFS nor median OS showed statistically significant difference between each two groups in the patients with partial remission in first?line chemotherapy ( P>0.05 for all) . In the limited stage, the median PFS in the control group, 4?week maintenance therapy group, and 6?week maintenance therapy group was 5.0, 6.5, and 4.0 months, respectively, and median OS was 11.0, 13.5, and 13.0 months, respectively, the differences showed no statistical significance ( P>0.05 for all) . In the extensive stage, the median PFS in the control group, 4?week maintenance therapy group, and 6?week maintenance therapy group was 3.0, 3.0, and 3.5 months, respectively, showing significant differences ( P=0.015);the median OS was 6.5, 8.0, and 8.0 months, respectively, presenting no statistically significant differences (P=0.096). In addition, the PFS in the 6?week maintenance therapy group was significantly improved as compared with that in the control group ( P=0. 016 ) . Compared with the control group, the incidence rates of nausea ( grade 3?4 ) , vomiting, hypodynamia, leukopenia, neutropenia, and thrombocytopenia in the 4?week maintenance therapy group and 6?week maintenance therapy group were increased significantly ( P<0.05 for all) , however, the side effects were tolerable. Conclusion Prolonging the treatment cycle of EP therapy can improve the PFS in SCLC patients in first?line CR chemotherapy and extensive stage.

Objective:To assess the prevalence of metabolic syndrome(MS) and its relationship with hyperuricemia(HUA) in perimenopausal women in Anning city, Yunnan province.Methods:This is a cross-sectional survey. In May 2021, a multi-stage stratified sampling method was used to collect demographics and clinical data [ethnicity, living community, height, weight, waist circumference, blood pressure, fasting plasma glucose, triglycerides(TG), serum uric acid, high density lipoprotein-cholesterol(HDL-C), alanine transaminase(ALT), etc] in a total of 6 721 perimenopausal women aged 45-60 years.Results:A total of 6 721 perimenopausal women were included in this study. The prevalences of MS and HUA were 14.05%(95% CI 13.22%-14.88%) and 6.46%(95% CI 5.88%-7.07%), respectively. The average age, HDL-C, urea, direct bilirubin, and albumin levels in the perimenstrual HUA population were lower than those in the non-HUA population while the levels of TG, ALT, heart rate, body mass index(BMI), and creatinine were higher(all P<0.05). The prevalence of HUA in perimenopausal women with ethnic minorities and family history of chronic diseases was higher than that in Han nationality and without family history of chronic diseases. The prevalence of MS in perimenopausal women was increased with the increase of serum uric acid( Z=-15.313 8, P<0.001). Multivariate logistic regression model showed that HUA was positively correlated with MS( OR=1.526, 95% CI 1.192-1.954) after adjusting for covariates such as BMI and ethnicity, and the incidence of MS in perimenopausal women in HUA group was 1.526 folds higher than that in non-hyperuricemia group. Conclusion:HUA is highly positively correlated with MS in perimenopausal women. The management of uric acid level in perimenopausal women should be strengthened.